The Technical Analyst
Checkpoint Therapeutics [CKPT]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Checkpoint Therapeutics Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-8.75% $1.460
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 51.08 mill |
| EPS: | -3.17 |
| P/E: | -0.460 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 34.99 mill |
| Avg Daily Volume: | 0.501 mill |
| RATING 2024-04-19 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | |||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.460 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.08x |
| Company: PE -0.460 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.256 (-82.49%) $-1.204 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.335 - 1.585 ( +/- 8.56%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-20 | Fortress Biotech, Inc. | Buy | 193 905 | COMMON STOCK, PAR VALUE $0.0001 |
| 2024-03-12 | Amit Sharma | Sell | 0 | Common Stock (Restricted) |
| 2024-02-28 | Oliviero James F Iii | Sell | 5 894 | COMMON STOCK |
| 2024-02-28 | Oliviero James F Iii | Sell | 9 056 | COMMON STOCK |
| 2024-02-28 | Gray William Garrett | Sell | 2 035 | Common Stock |
| INSIDER POWER |
|---|
| 82.00 |
| Last 98 transactions |
| Buy: 5 337 828 | Sell: 1 367 663 |
Forecast:
16:00 - $1.460
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.460
Forecast 2: 16:00 - $1.460
Forecast 3: 16:00 - $1.460
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.460 (-8.75% ) |
| Volume | 0.755 mill |
| Avg. Vol. | 0.501 mill |
| % of Avg. Vol | 150.84 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CKPT
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $1.969 | N/A | Active |
|---|
CKPT
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
Last 10 Buy Signals
Latest Press Releases
2024-04-19 14:38:00 - Press Release
Rosen, Top Ranked Global Counsel, Encourages Checkpoint Therapeutics, Inc. Investors To Secure Counsel Before Important Deadline In Securities Class Action - Ckpt
New york , april 19, 2024 /prnewswire/ -- why: rosen law firm, a global investor rights law firm, reminds purchasers of securities of checkpoint therapeutics, inc. (nasdaq: ckpt) between march 10, 2021 and december 15, 2023, both dates inclusive (the "class period"), of the important june 4, 2024 lead plaintiff deadline. so what: if you purchased checkpoint securities during the class period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
2024-04-19 12:47:00 - Press Release
Glancy Prongay & Murray Llp Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against Checkpoint Therapeutics, Inc. (ckpt)
Los angeles--(business wire)--glancy prongay & murray llp (“gpm”) reminds investors of the upcoming june 4, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired checkpoint therapeutics, inc. (“checkpoint” or the “company”) (nasdaq: ckpt) securities between march 10, 2021 and december 15, 2023, inclusive (the “class period”). if you suffered a loss on your checkpoint investments or would like to inquire about poten.
2024-04-19 07:00:00 - Press Release
Deadline Action Alert: The Schall Law Firm Encourages Investors In Checkpoint Therapeutics, Inc. With Losses To Contact The Firm
Los angeles, ca / accesswire / april 19, 2024 / the schall law firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against checkpoint therapeutics, inc. ("checkpoint" or "the company") (nasdaq:ckpt) for violations of 10(b) and 20(a) of the securities exchange act of 1934 and rule 10b-5 promulgated thereunder by the u.s. securities and exchange commission. investors who purchased the company's securities between march 10, 2021 and december 15, 2023, inclusive (the "class period"), are encouraged to contact the firm before june 4, 2024.
2024-04-18 13:11:00 - Press Release
Deadline Reminder: Law Offices Of Howard G. Smith Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against Checkpoint Therapeutics, Inc. (ckpt)
Bensalem, pa.--(business wire)--law offices of howard g. smith reminds investors of the upcoming june 4, 2024 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased checkpoint therapeutics, inc. (“checkpoint” or the “company”) (nasdaq: ckpt) securities between march 10, 2021 and december 15, 2023, inclusive (the “class period”). investors suffering losses on their checkpoint investments are encouraged to contact the law offices of howard g. smith to disc.
2024-04-18 08:00:00 - Press Release
Shareholder Action Alert: The Schall Law Firm Encourages Investors In Checkpoint Therapeutics, Inc. With Losses To Contact The Firm
Los angeles, ca / accesswire / april 18, 2024 / the schall law firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against checkpoint therapeutics, inc. ("checkpoint" or "the company") (nasdaq:ckpt) for for violations of 10(b) and 20(a) of the securities exchange act of 1934 and rule 10b-5 promulgated thereunder by the u.s. securities and exchange commission. investors who purchased the company's securities between march 10, 2021 and december 15, 2023, inclusive (the "class period"), are encouraged to contact the firm before june 4, 2024.
Latest News
2023-12-18 12:22:54 - Proactive Investors
Checkpoint Therapeutics stock plunges on FDA setback
Checkpoint Therapeutics (NASDAQ:CKPT) Inc shares plummeted 48% to $1.72 in midday trading on Monday after the US Food and Drug Administration (FDA) failed to approve its drug development candidate Cosibelimab, the clinical-stage immunotherapy and targeted oncology company's experimental therapy to treat a type of advanced skin cancer. In its complete response letter (CRL), the FDA cited issues related to a third-party contract manufacturer as the reason for its decision.
2023-12-18 08:43:00 - Reuters
Checkpoint Therapeutics slides after US FDA declines cancer therapy approval
Checkpoint Therapeutics said on Monday the U.S. Food and Drug Administration had declined to approve its experimental therapy to treat a form of skin cancer following an inspection at a contract manufacturer, sending its shares down nearly 50%.
2023-12-11 12:26:14 - InvestorPlace
3 Biotech Stocks to Turn $5,000 Into $1 Million: December 2023
Some of the most explosive opportunities can be found in biotech stocks. Look at CRISPR Therapeutics (NASDAQ: CRSP ), for example.
2023-12-06 14:48:10 - PennyStocks
Best Penny Stocks To Buy? 4 To Watch With Big News This Week
Penny stocks, securities with share prices under $5, offer investors a chance at exponential returns with little upfront investment. However, investing wisely in penny stocks requires research as their prices fluctuate wildly around key events.
2023-09-21 08:30:00 - GlobeNewsWire
Checkpoint Therapeutics to Participate in the Cantor Global Healthcare Conference
WALTHAM, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a panel presentation at the Cantor Global Healthcare Conference on Thursday, September 28, 2023, at 10:20 a.m. ET in New York City. The Company will also attend in-person one-on-one meetings during the conference.
2023-08-01 19:01:20 - Seeking Alpha
Checkpoint: PDUFA Date Catalyst Makes This A Must Watch
A PDUFA date of January 3, 2024 has been established by which FDA will decide upon by then whether or not cosibelimab should be approved for the treatment of cSCC. It is said that the cutaneous squamous cell carcinoma market in the U.S. alone could reach $1.6 billion. Company plans to compete with other PD-1/PD-L1 inhibitors in terms of mechanism of action, which gives cosibelimab an improved safety profile over other drugs in the same class.
2023-07-30 04:19:15 - Seeking Alpha
Checkpoint Therapeutics: Cosibelimab Data Bolsters Case For Dual-Approval In cSCC
Checkpoint Therapeutics announced updated, longer-term data for cosibelimab from their pivotal trial in locally advanced and metastatic cutaneous squamous cell carcinoma “cSCC”. The data revealed improved response over time with higher complete response rates compared to previous readouts. The responses were durable with the median duration of response not yet reached. Checkpoint believes cosibelimab has a shot at a $1.6B market opportunity, yet, CKPT continues to trade in the gutter with a market cap of around $61M.
2023-05-21 10:03:52 - InvestorPlace
3 Stocks With 1,000% Upside Potential
If you're a risk taker on the lookout for stocks with 1000% upside potential, you'd have to venture into speculative territory. It is difficult to find analyst ratings with such a high upside potential unless catalysts could propel the stock that high.
2023-05-11 16:40:00 - InvestorPlace
3 Penny Stocks That Could Make You a Millionaire by 2025
Penny stocks have had a great start this year, but with uncertainty starting to rear its head again, investors have started to choose safer options instead. Indeed, the underlying businesses of most penny stocks are loss-making startups that depend on external sources to survive in the long run.
2023-01-10 13:40:19 - Seeking Alpha
Checkpoint Therapeutics: An Updated Analysis
We are checking back in on a small developmental company called Checkpoint Therapeutics, Inc. The company is planning to submit a BLA targeting two indications for its lead product candidate cosibelimab later this month.